EP Patent

EP2100598A1 — Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease

Assigned to Almirall SA · Expires 2009-09-16 · 17y expired

What this patent protects

This invention relates to a novel dosage for aclidinium and to novel methods and formulations for the treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), using aclidinium.

USPTO Abstract

This invention relates to a novel dosage for aclidinium and to novel methods and formulations for the treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), using aclidinium.

Drugs covered by this patent

Patent Metadata

Patent number
EP2100598A1
Jurisdiction
EP
Classification
—
Expires
2009-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Almirall SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.